Selinexor: Targeting a novel pathway in multiple myeloma.

EJHaem · 2023 · PMC10435704 · PMID 37601856

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A trend toward an OS benefit was also seen (HR 0.84) at the primary analysis, but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.